Clinical Trial Update: Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating PDS0101 in combination with pembrolizumab for HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hpv-associated Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• PDS0101
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: PDS Biotechnology Corp. | Conditions: Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING